.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,309,605

« Back to Dashboard

Claims for Patent: 8,309,605

Title:Enhanced bimatoprost ophthalmic solution
Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:12/965,514
Patent Claims: 1. A method of lowering elevated intraocular pressure in a patient with open-angle glaucoma or ocular hypertension which comprises applying to the eyes of the patient an aqueous solution comprised of: about 0.01% w/v bimatoprost; about 200 ppm benzalkonium chloride; the solution having a pH of about 7.3; a phosphate buffer; and, water.

2. The method of claim 1 wherein the bimatoprost is present in a concentration of 0.01% w/v and the phosphate buffer is dibasic sodium phosphate.

3. The method of claim 1 further comprising 0.03% EDTA.

4. The method of claims 1 or 2 wherein the patient applies the aqueous solution at least once a day.

5. The method of claim 4 wherein the patient applies the aqueous solution once a day.

6. A method of lowering intraocular pressure in a patient suffering from elevated intraocular pressure which comprises applying to the eyes of the patient an aqueous solution comprising: 0.01% w/v bimatoprost; about 200 ppm benzalkonium chloride; the solution having a pH of about 7.3; a citric acid buffer; and, water.

7. The method of claim 6 wherein the method is applied to patients suffering from glaucoma.

8. The method of claim 6 wherein the citric acid buffer is present in a concentration of about 0.01% w/v.

9. The method of claim 6 wherein the method is applied once a day.

10. The method of claim 7 wherein the glaucoma is open angle glaucoma.

11. The method of claim 6 wherein the solution comprises 200 ppm benzalkonium chloride.

12. A method of treating glaucoma in a patient comprising the following steps: applying at least once a day a formulation comprising: about 0.01% w/v bimatoprost; benzalkonium chloride in the amount of about 200 ppm; at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA; and wherein the formulation has a pH of about 7.3.

13. The method of claim 12 wherein the formulation is an aqueous solution.

14. The method of claim 12 wherein the buffering agent is dibasic sodium phosphate heptahydrate.

15. The method of claim 12 wherein the buffering agent is citric acid monohydrate.

16. The method of claim 12 wherein the buffering agent is EDTA.

17. The method of claim 13 further comprising purified water.

18. A method of lowering elevated intraocular pressure in a patient with open-angle glaucoma or ocular hypertension which comprises applying to the eyes of the patient an aqueous solution comprising: 0.01% w/v bimatoprost; 0.02% w/v benzalkonium chloride; at least two buffering agents selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA; hydrochloric acid and sodium hydroxide to adjust the solution to a pH of about 7.3; sodium chloride; and, purified water.

19. The method of claim 18 wherein one of the buffering agents is citric acid monohydrate.

20. The method of claim 18 wherein the solution is applied to the patient's eyes at least once a day.

21. The method of claim 18 wherein one of the buffering agents is dibasic sodium phosphate heptahydrate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc